Bristol Myers Squibb

News

BMS doubles down on BridgeBio alliance on SHP2 drugs

Bristol-Myers Squibb's flurry of dealmaking has continued with en expansion of its partnership with BridgeBio on drugs targeting SHP2, in the hope of combining them with its cancer immunoth

News

BMS pays $200m to expand Evotec alliance on protein degrader...

Bristol-Myers Squibb's Celgene unit has clearly been impressed by progress in its four-year-old alliance with Evotec on protein degradation.

News

BMS bags FDA okay for cardiomyopathy drug mavacamten

Bristol-Myers Squibb's has become the first company to bring a cardiac myosin inhibitor through to FDA approval, claiming a green light from the US regulator for mavacamten as a therapy for

News

End of the line for BMS, Nektar's bempegaldesleukin/Opdivo a...

Four years after Bristol-Myers Squibb paid $1.85 billion upfront to make Nektar's bempegaldesleukin a companion drug to its cancer immunotherapy Opdivo, the alliance is being discontinued.<

News

Cytokinetics' heart drug omecamtiv strikes out in heart fail...

Cytokinetics' hopes of resurrecting cardiac myosin activator omecamtiv mecarbil have suffered another setback, after the drug failed to show a benefit in a phase 3 heart failure study.

News

Gilead beats BMS to FDA okay for early lymphoma CAR-T therap...

Gilead Sciences' Kite Pharma has become the first drugmaker to get FDA approval to use a CAR-T therapy after just one earlier systemic therapy, moving the approach up the treatment pathway.

BMS doubles down on BridgeBio alliance on SHP2 drugs

BMS pays $200m to expand Evotec alliance on protein degrader...

BMS bags FDA okay for cardiomyopathy drug mavacamten

End of the line for BMS, Nektar's bempegaldesleukin/Opdivo a...

Cytokinetics' heart drug omecamtiv strikes out in heart fail...

Gilead beats BMS to FDA okay for early lymphoma CAR-T therap...

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

Bristol Myers Squibb

Editor's Picks